

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF: Michael R. JOHNSON  
SERIAL NO: New Application  
FILED: Herewith  
FOR: SODIUM CHANNEL BLOCKERS

**INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97**

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

**REFERENCES**

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references were filed in prior application Serial No. 10/076,551, filed February 19, 2002, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

**RELATED CASES**

- Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

**CERTIFICATION**

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

**DEPOSIT ACCOUNT**

- Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

James J. Kelly  
Registration No. 41,504

Customer Number

22850

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)

Form PTO 1449 (Modified)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  LIST OF REFERENCES CITED BY APPLICANT	ATTY DOCKET NO. 251537US96DIV	SERIAL NO. New Application
		APPLICANT Michael R. JOHNSON	
		FILING DATE Herewith	GROUP

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	4,177,285	12-04-79	Cragoe, Jr. et al.			
	AB	3,794,734	02-26-74	Cragoe, Jr. et al.			
	AC	3,864,401	02-04-75	Schultz et al.			
	AD	3,914,253	10-21-75	Cragoe, Jr. et al.			
	AE	3,929,872	12-30-75	Cragoe, Jr. et al.			
	AF	3,931,239	01-06-76	Cragoe, Jr. et al.			
	AG	3,953,476	04-27-76	Cragoe, Jr. et al.			
	AH	3,966,966	06-29-76	Cragoe, Jr. et al.			
	AI	4,006,180	02-01-77	Cragoe, Jr. et al.			
	AJ	4,012,524	03-15-77	Cragoe, Jr. et al.			
	AK	4,159,279	06-26-79	Smith et al.			
	AL	4,163,781	08-07-79	Cragoe, Jr. et al.			
	AM	4,163,794	08-07-79	Cragoe, Jr. et al.			
	AN	4,085,219	04-18-78	Cragoe, Jr. et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	NO
	AO					
	AP					
	AQ					
	AR					
	AS					
	AT					
	AU					
	AV					

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

AW	R. Tarran et al., <u>The CF Salt Controversy: In Vivo Observations and Therapeutic Approaches</u> , <i>Molecular Cell</i> , Vol. 8, 149-158, July 2001.
AX	Michael R. Knowles et al., <u>Amiloride in Cystic Fibrosis: Safety, Pharmacokinetics, and Efficacy in the Treatment of Pulmonary Disease</u> , Chapter 20, page 301-316.
AY	Louis Simchowitz et al., <u>An Overview of the Structure Activity Relations in the Amiloride Series</u> , Chapter 2, page 9-25.
AZ	J.R. Sabater et al., <u>Aerosolization of P2y2-Receptor Agonists Enhances Mucociliary Clearance in Sheep</u> , <i>The American Physiological Society</i> , page 2191-2196.

Examiner	Date Considered
----------	-----------------

\*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.